Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration
- PMID: 38427312
- DOI: 10.1007/s10549-024-07255-4
Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration
Abstract
Purpose: Hotspot estrogen receptor alpha (ER/ESR1) mutations are recognized as the driver for both endocrine resistance and metastasis in advanced ER-positive (ER+) breast cancer, but their contributions to metastatic organ tropism remain insufficiently understood. In this study, we aim to comprehensively profile the organotropic metastatic pattern for ESR1 mutant breast cancer.
Methods: The organ-specific metastatic pattern of ESR1 mutant breast cancer was delineated using multi-omics data from multiple publicly available cohorts of ER+ metastatic breast cancer patients. Gene mutation/copy number variation (CNV) and differential gene expression analyses were performed to identify the genomic and transcriptomic alterations uniquely associated with ESR1 mutant liver metastasis. Upstream regulator, downstream pathway, and immune infiltration analysis were conducted for subsequent mechanistic investigations.
Results: ESR1 mutation-driven liver tropism was revealed by significant differences, encompassing a higher prevalence of liver metastasis in patients with ESR1 mutant breast cancer and an enrichment of mutations in liver metastatic samples. The significant enrichment of AGO2 copy number amplifications (CNAs) and multiple gene expression changes were revealed uniquely in ESR1 mutant liver metastasis. We also unveiled alterations in downstream signaling pathways and immune infiltration, particularly an enrichment of neutrophils, suggesting potential therapeutic vulnerabilities.
Conclusion: Our data provide a comprehensive characterization of the behaviors and mechanisms of ESR1 mutant liver metastasis, paving the way for the development of personalized therapy to target liver metastasis for patients with ESR1 mutant breast cancer.
Keywords: ER mutation; Immune filtration; Liver tropism; Metastatic breast cancer; Molecular changes.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Breast Cancer Res. 2017 May 23;19(1):60. doi: 10.1186/s13058-017-0851-4. Breast Cancer Res. 2017. PMID: 28535794 Free PMC article.
-
The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).Cancer Treat Res Commun. 2019;19:100123. doi: 10.1016/j.ctarc.2019.100123. Epub 2019 Feb 21. Cancer Treat Res Commun. 2019. PMID: 30826563
-
Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.Clin Cancer Res. 2019 Dec 15;25(24):7485-7496. doi: 10.1158/1078-0432.CCR-19-1129. Epub 2019 Sep 23. Clin Cancer Res. 2019. PMID: 31548345
-
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Br J Cancer. 2022 Feb;126(2):174-186. doi: 10.1038/s41416-021-01564-x. Epub 2021 Oct 7. Br J Cancer. 2022. PMID: 34621045 Free PMC article. Review.
-
ESR1 mutations in breast cancer.Cancer. 2019 Nov 1;125(21):3714-3728. doi: 10.1002/cncr.32345. Epub 2019 Jul 18. Cancer. 2019. PMID: 31318440 Free PMC article. Review.
Cited by
-
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden.NPJ Breast Cancer. 2025 Jan 14;11(1):3. doi: 10.1038/s41523-024-00715-6. NPJ Breast Cancer. 2025. PMID: 39809806 Free PMC article.
-
Regulation of metastatic organotropism.Trends Cancer. 2025 Mar;11(3):216-231. doi: 10.1016/j.trecan.2024.11.012. Epub 2024 Dec 27. Trends Cancer. 2025. PMID: 39732596 Review.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 71:209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113–126. https://doi.org/10.1111/joim.12084 - DOI - PubMed - PMC
-
- Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456. https://doi.org/10.1038/nrc1370 - DOI - PubMed
-
- Wu Y, Sarkissyan M, Vadgama JV (2016) Epithelial-mesenchymal transition and breast cancer. J Clin Med 5:13. https://doi.org/10.3390/jcm5020013 - DOI - PubMed - PMC
-
- Ye X, Brabletz T, Kang Y, Longmore GD, Nieto MA, Stanger BZ, Yang J, Weinberg RA (2017) Upholding a role for EMT in breast cancer metastasis. Nature 547:E1–E3. https://doi.org/10.1038/nature22816 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous